Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird
Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...
HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings
HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...
Denali Therapeutics (NASDAQ:DNLI) Given New $87.00 Price Target at HC Wainwright
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 3,080 Shares of Stock
Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The ...
ETF Daily News3d
Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% on Insider Selling
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) shares traded down 4.1% on Monday following insider selling activity. The stock traded as low as $20.25 and last traded at $20.39.
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...
ETF Daily News12d
Stifel Financial Corp Trims Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)
Stifel Financial Corp cut its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 23.4% in the third quarter, Holdings Channel reports.The firm owned 9,839 shares of the company ...